Boston Scientific recently announced it entered into a definitive agreement to acquire SoniVie Ltd. According to the press release, SoniVie is a privately held medical device company that developed the TIVUS Intravascular Ultrasound System.
SoniVie describes TIVUS as an intravascular, catheter-based technology that performs denervation of nerves surrounding the blood vessels (including renal artery denervation) to treat hypertensive disorders. Inceased sympathetic nerve activity between the kidneys and brain sometimes results in elevated blood pressure. TIVUS reduces blood pressure by disrupting that nerve activity with ultrasonic energy, causing blood vessels to relax and safely lowering blood pressure.
Commenting on the agreement, Lance Bates, Boston Scientific’s SVP and President of Interventional Cardiology Therapies, said “Renal denervation for hypertension is an exciting medical advancement for the millions of patients it may help and is supported by positive results from contemporary clinical trials and ongoing research.” Bates continued that Boston Scientific believes “the addition of the ultrasound-based TIVUS system can complement their expansive interventional portfolio with a minimally invasive therapy for patients with hypertension.”
The deal is expected to close in the first half of 2025 and is valued at approximately $540 million. The agreement to acquire involves Boston Scientific paying about $360 million for the 90% of SoniVie’s equity that Boston Scientific does not already own, plus up to an additional $180 million payment if SoniVie achieves a regulatory milestone.
Boston Scientific’s press release is available here.
